Royalty Pharma Completes $240M Deal for Full Evrysdi Royalty Rights
Royalty Pharma acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream.
/ 1662 items
#XY↓
Verastem Stops Lung Cancer Trial to Focus on More Promising Treatment
Verastem Oncology discontinues RAMP 203 trial for KRAS G12C lung cancer to prioritize VS-7375, showing 69% response rate in KRAS G12D patients.
Greenwich LifeSciences Extends Share Lock-up Through 2026
Greenwich LifeSciences (GLSI) announces 6-year share lock-up extension for directors and officers to support FLAMINGO-01 breast cancer trial through September 2026.
Genmab Stops Development of Acasunlimab to Focus on Key Cancer Treatments
Genmab discontinues acasunlimab development to prioritize high-impact cancer therapies including EPKINLY, petosemtamab, and Rina-S in its late-stage pipeline.
D. Boral Starts Coverage on Turn Therapeutics with Buy Rating and $8 Target
D. Boral Capital begins coverage of Turn Therapeutics with a Buy rating, citing strong dermatology focus, upcoming clinical data, and long-term growth potential.
Needham Raises Autolus Target to $11, Sees Strong Upside Into 2026
Needham boosts Autolus Therapeutics price target to $11, keeps Buy rating, and highlights breakeven potential and upside from obe-cel and Aucatzyl.